» Articles » PMID: 35323310

A Population-Based Study to Evaluate the Associations of Nodal Stage, Lymph Node Ratio and Log Odds of Positive Lymph Nodes with Survival in Patients with Small Bowel Adenocarcinoma

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2022 Mar 24
PMID 35323310
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This study aimed to determine the real-world prognostic significance of lymph node ratio (LNR) and log odds of positive lymph nodes (LOPLN) in patients with non-metastatic small bowel adenocarcinoma.

Methods: Patients diagnosed with early-stage small bowel adenocarcinoma between January 2007 and December 2018 from a large Canadian province were identified. We calculated the LNR by dividing positive over total lymph nodes examined and the LOPLN as log ([positive lymph nodes + 0.5]/[negative lymph nodes + 0.5]). The LNR and LOPLN were categorized at cut-offs of 0.4 and -1.1, respectively. Multivariable Cox proportional hazards models were constructed for each nodal stage, LNR and LOPLN, adjusting for measured confounding factors. Harrell's C-index and Akaike's Information Criterion (AIC) were used to calculate the prognostic discriminatory abilities of the different models.

Results: We identified 141 patients. The median age was 67 years and 54.6% were men. The 5-year overall survival rates for patients with stage I, II and III small bowel adenocarcinoma were 50.0%, 56.6% and 47.5%, respectively. The discriminatory ability was generally comparable for LOPLN, LNR and nodal stage in the prognostication of all patients. However, LOPLN had higher discriminatory ability among patients with at least one lymph node involvement (Harrell's C-index, 0.75, 0.77 and 0.82, and AIC, 122.91, 119.68 and 110.69 for nodal stage, LNR and LOPLN, respectively).

Conclusion: The LOPLN may provide better prognostic information when compared to LNR and nodal stage in specific patients.

Citing Articles

Platelet-lymphocyte ratio as a predictor of lymph node metastasis in small bowel cancer.

Chen X, Liu Z, Song J, Li J J Robot Surg. 2024; 18(1):172.

PMID: 38613728 DOI: 10.1007/s11701-024-01915-9.


The Prognostic Utility of the Metastatic Lymph Node Ratio and the Number of Regional Lymph Nodes Removed from Patients with Small Bowel Adenocarcinomas.

Aydin D, Kefeli U, Ozcelik M, Erdem G, Sendur M, Yildirim M Medicina (Kaunas). 2023; 59(8).

PMID: 37629761 PMC: 10456871. DOI: 10.3390/medicina59081472.

References
1.
Pei J, Zhang C, Fan Y, Dai D . Comparison of Different Lymph Node Staging Systems in Patients With Resectable Colorectal Cancer. Front Oncol. 2019; 8:671. PMC: 6340930. DOI: 10.3389/fonc.2018.00671. View

2.
Halfdanarson T, McWilliams R, Donohue J, Quevedo J . A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg. 2010; 199(6):797-803. DOI: 10.1016/j.amjsurg.2009.05.037. View

3.
Dabaja B, Suki D, Pro B, Bonnen M, Ajani J . Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004; 101(3):518-26. DOI: 10.1002/cncr.20404. View

4.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

5.
von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007; 370(9596):1453-7. DOI: 10.1016/S0140-6736(07)61602-X. View